Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays

Mustafa A. Barbhuiya, Manoj K. Kashyap, Vinuth N. Puttamallesh, Rekha Vijay Kumar, Xinyan Wu, Akhilesh Pandey, Harsha Gowda

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The vast majority of esophageal cancers in China, India and Iran are esophageal squamous cell carcinomas (ESCC). A timely diagnosis provides surgical removal as the main therapeutic option for patients with ESCC. Currently, there are no targeted therapies available for ESCC. We carried out reverse phase protein array-based protein expression profiling of seven ESCC-derivedcell lines and a non-neoplastic esophageal epithelial cell line (Het-1A) to identify differentially expressed proteins in ESCC. SYK non-receptortyrosine kinase was overexpressed in six out of seven ESCC cell lines that were used in the study. We evaluated the role of SYK in ESCC using the pharmacological inhibitor entospletinib (GS-9973) and siRNA-based knock down studies. Entospletinib is a selective inhibitor of SYK, which is currently being evaluated in phase II clinical trials for hematological malignancies. Using in vivo subcutaneous tumor xenografts in mice, we demonstrate that treatment with entospletinib significantly inhibits tumor growth. Further clinical studies are needed to prove the efficacy of entospletinib as a targeted therapeutic agent for treating ESCC.

Original languageEnglish (US)
Pages (from-to)18422-18434
Number of pages13
JournalOncotarget
Volume9
Issue number26
DOIs
StatePublished - Apr 1 2018

Keywords

  • ESCC
  • Entospletinib
  • RPPA
  • SYK

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays'. Together they form a unique fingerprint.

Cite this